论文部分内容阅读
目的:观察多西他赛(TAX)联合奥沙利铂(L-OHP)、希罗达方案与FOLFOX4方案治疗进展期胃癌的疗效及不良反应。方法:治疗组24例晚期胃癌患者接受TAX联合L-OHP、希罗达化疗,对照组24例接受FOLFOX4化疗。结果:治疗组总有效率为54.7%,中位疾病进展时间(TTP)为6.7个月;对照组总有效率为41.6%,中位TTP为5.8个月。结论:TAX联合L-OHP、希罗达化疗方案治疗晚期胃癌近期疗效显著,耐受性较好。
Objective: To observe the efficacy and side effects of docetaxel (TAX) plus oxaliplatin (L-OHP), Xeloda and FOLFOX4 in the treatment of advanced gastric cancer. Methods: Twenty-four patients with advanced gastric cancer in the treatment group received TAX combined with L-OHP and Xeloda chemotherapy, and 24 in the control group received FOLFOX4 chemotherapy. Results: The total effective rate was 54.7% in the treatment group and 6.7 months in the median disease progression time (TTP). The total effective rate in the control group was 41.6% and the median TTP was 5.8 months. Conclusion: TAX combined with L-OHP and Xeloda chemotherapy for advanced gastric cancer has obvious curative effect and good tolerance.